Roche gets FDA nod for Phesgo to treat HER2-positive breast cancer

This article was originally published here

Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, which is administered by subcutaneous injection in combination with intravenous (IV) chemotherapy. Phesgo is said

The post Roche gets FDA nod for Phesgo to treat HER2-positive breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply